Tolerance and Efficacy Evaluation of 3 Face Creams

NCT ID: NCT02063971

Last Updated: 2014-02-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-12-31
• Study Completion Date: 2014-06-30

Brief Summary

The study will evaluate the tolerance and the efficacy on skin comfort of F#1048-082 soothing cream used just after injection procedure and also the tolerance and the efficacy of the F#841-020 anti-age cream on aging parameters compared to baseline and to the F#1374-002 placebo cream (comparison within subjects - half face method) to identify additional benefits delivered by the product compared to a cosmetic procedure.

Detailed Description

First study phase (soothing activity)

• Clinical grading (visual analogic scale):

1. Erythema (0= no erythema to 10= strong erythema)

2. Oedema (0= no oedema to 10= strong oedema)

3. Bruise (0= no bruise to 10= strong bruise)

4. Overall skin appearance (0= bad overall appearance to 10= good overall appearance).

• Optical colorimetry: measurement of redness/bruise (L*a*b*) by Spectrophotometer CM-2600d.
• Photographic documentation: Canfield imaging station equipped with visible, polarized, fluorescence and UV light and with specific lighting for shadows.

Second study phase (anti-age activity vs placebo):

• Clinical and self grading (visual analogic scale) :

1. Forehead wrinkles (0= no wrinkle to 10= severe wrinkles)

2. Crow's feet wrinkles (0= no wrinkle to 10= severe wrinkles)

3. Crow's feet fine lines (0= no fine line to 10= severe fine lines)

4. Under the eye wrinkles (0= no wrinkle to 10= severe wrinkles)

5. Under the eye fine lines (0= no fine line to 10= severe fine lines)

6. Frown lines (0= no wrinkle to 10= severe wrinkles)

7. Marionette lines (0= no wrinkle to 10= severe wrinkles)

8. Upper lip wrinkles (0= no wrinkle to 10= severe wrinkles)

9. Nasolabial folds (0= no wrinkle to 10= severe wrinkles)

10. Cheek wrinkles (0= no wrinkle to 10= severe wrinkles)

11. Neck wrinkles (0= no wrinkle to 10= severe wrinkles)

12. Lines on the neck opening (0= no wrinkle to 10= severe wrinkles)

13. Skin firmness (0= very firm skin to 10= no firm skin)

14. Skin elasticity (0= very elastic skin to 10= no elastic skin)

15. Sagging skin (0= no sagging skin to 10= severe sagging skin)

16. Radiance (0= very radiant skin to 10= no radiant skin)

17. Smoothness (0= very smooth skin to 10= no smooth skin)

18. Skin softness (0= very soft skin to 10= no soft skin)

19. Colour evenness (0= good evenness to 10= bad evenness)

20. Skin tone (0= good complexion to 10= bad complexion)

• Optical colorimetry: measurement of skin colour (L*a*b*) by Spectrophotometer CM-2600d.
• Photographic documentation: Canfield imaging station equipped with visible, polarized, fluorescence and UV light and with specific lighting for shadows.
• Skin replicas and profilometry at level of crow's feet (image analysis of: total surface of the wrinkles, mean length of the wrinkles, total length of the wrinkles, number of the wrinkles)
• Skin elasticity measurement by suction (Cutometer®)

Tolerance evaluation (investigator's judgement):

At each evaluation time, the investigator considering the appearance of possible adverse effects related to the tested creams and all comments reported by the subjects on diary card will judge the tolerance of the products under study.

Conditions

Skin Aging

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Skin aging

Anti-age product will be applied once a day, in the evening, on half face and neck for an uninterrupted period of 12 weeks and the placebo cream in the morning with the same modalities. On the contralateral face side (right or left side according to a previous randomisation list), the volunteers will apply the placebo cream twice a day

Group Type: EXPERIMENTAL

Soothing (formulation number: F#1048-082) and antiaging creams (F#841-020 and F#1374-002)

Intervention Type: OTHER

Interventions

Soothing (formulation number: F#1048-082) and antiaging creams (F#841-020 and F#1374-002)

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• female gender
• age > 35 years old
• good general state of health
• woman who had already undergone Hyaluronic acid injections
• woman who have not applied any retinoid product in the last 3 months
• woman who are not in a recovery period after laser/peeling/acne treatment
• accepting to return to the centre for the planned visits
• accepting to follow the investigator's instructions during the entire study period
• agreeing to present at each study visit without make-up
• accepting to not change their habits regarding: food, physical activity, face cleansing and make-up use
• agreeing to not receive any drug able to change the skin characteristics during the entire duration of the study
• accepting to not receive any cutaneous anti-age treatment during the entire duration of the study
• accepting not to expose their face to strong UV irradiation (UV session or sun bathes) during the entire duration of the study
• accepting to sign the Informed consent form.

Exclusion Criteria

• Pregnancy (only for subjects not in menopause)
• lactation (only for subjects not in menopause)
• subjects not in menopause who do not use adequate contraceptive precautions in order to avoid pregnancies during the study;
• subjects not in menopause who do not accept to perform the pregnancy test during the basal visit (T0), 6 and 12 weeks after the intradermal implant execution;
• subjects participating to a similar test less than 3 months ago
• sensitivity to the test products or theirs ingredients
• subjects whose insufficient adhesion to the study protocol is foreseeable.
• dermatitis
• presence of cutaneous disease on the tested area as lesions, scars, malformations.
• clinical and significant skin condition on the test area (e.g. active eczema, dermatitis, psoriasis etc.)
• recurrent facial/labial herpes.
• diabetes
• endocrine disease
• hepatic disorder
• renal disorder
• cardiac disorder
• pulmonary disease
• digestive disease
• haematological disease
• chronic phlogosis or autoimmune disease
• cancer
• neurological or psychological disease
• drug allergy.
• systemic corticosteroids
• retinoid products in the previous 3 months and during the entire study period
• aspirin or non-steroid anti-inflammatory drugs (FANS)
• anti-histaminic, narcotic, antidepressant, immunosuppressive drugs (with except, for female subjects, of contraceptive or hormonal treatment starting from at least one year)
• assumption of drugs able to influence the test results in the investigator opinion.

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Adele Sparavigna

OTHER

Sponsor Role: lead

Responsible Party

Adele Sparavigna

Physician

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

ADELE SPARAVIGNA, PHYSICIAN

Role: PRINCIPAL_INVESTIGATOR

Derming SRL

Locations

DERMING

Monza, Monza-brianza, Italy

Countries

Italy

Other Identifiers

E3513 / SC13-235

Identifier Type: -

Identifier Source: org_study_id